Patient characteristics, treatment and outcome
| Sex . | Median age, y (range) . | Stage/site at inclusion . | Median cycle number (range) . | Consolidation treatment after L-asparaginase . | Response after 3 cycles and outcome . | Median follow-up, months for all patients and surviving patients (range) . |
|---|---|---|---|---|---|---|
| Male: 15 | 60 (45-76) | IE /IIE: 12 | 3 (1-6) | ASCT (BEAM): 5 | CR: 11, PR: 3 | 12.3 (1-48) |
| Female: 4 | IV: 7 | RT: 1 | NR: 4, NE: 1 | 26.2 (17-48) | ||
| NOD: 8 | ||||||
| DOD: 10 | ||||||
| DUD: 1 |
| Sex . | Median age, y (range) . | Stage/site at inclusion . | Median cycle number (range) . | Consolidation treatment after L-asparaginase . | Response after 3 cycles and outcome . | Median follow-up, months for all patients and surviving patients (range) . |
|---|---|---|---|---|---|---|
| Male: 15 | 60 (45-76) | IE /IIE: 12 | 3 (1-6) | ASCT (BEAM): 5 | CR: 11, PR: 3 | 12.3 (1-48) |
| Female: 4 | IV: 7 | RT: 1 | NR: 4, NE: 1 | 26.2 (17-48) | ||
| NOD: 8 | ||||||
| DOD: 10 | ||||||
| DUD: 1 |
ASCT indicates autologous stem cell transplantation; BEAM, BCNU, etoposide, Ara-C, melphalan; RT, radiotherapy; CR, complete response; PR, partial response; NR, no response; NE, not evaluated; NOD, no evidence of disease; DOD, died of disease; and DUD, dead unrelated to disease.